腫瘍トランスクリプトミクス市場- 世界の産業規模、シェア、動向、機会、予測、腫瘍タイプ別、技術別、製品別、用途別、エンドユーザー別、地域別セグメント、2019年～2029年

腫瘍トランスクリプトミクスの世界市場規模は2023年に56億7,000万米ドルとなり、2029年までのCAGRは6.34%で予測期間の堅調な成長が予測されています。

腫瘍トランスクリプトミクスの世界市場は、ゲノム研究や個別化医療の進歩に後押しされ、著しい急成長を遂げています。腫瘍トランスクリプトミクスは腫瘍細胞内の遺伝子発現パターンを研究するもので、がんの生物学、進行、治療反応に関する貴重な洞察を提供します。この急成長市場は、次世代シーケンシング（NGS）、マイクロアレイ解析、定量ポリメラーゼ連鎖反応（qPCR）など、多数の革新的な技術やプラットフォームによって特徴付けられています。これらのツールにより、研究者や臨床医は遺伝子発現レベルのプロファイリング、バイオマーカーの同定、さまざまながん種に関与する分子経路の解明が可能になります。腫瘍トランスクリプトミクス市場の成長を促進する主な要因の一つは、精密腫瘍学ソリューションに対する需要の高まりです。腫瘍の複雑な分子シグネチャーを解読することで、ヘルスケアプロバイダーは個々の患者に合わせた治療を行うことができ、副作用を最小限に抑えながら治療効果を最適化することができます。さらに、新しいバイオインフォマティクス・アルゴリズムとデータ解析ツールの登場はデータ解釈に革命をもたらし、複雑なゲノムデータを臨床的に実用的な洞察に変換することを容易にしています。このような最先端技術と計算科学的アプローチの融合は、がんの診断、予後予測、治療法を再定義し、最終的には世界中の患者ケアのパラダイムを変革しようとしています。人口動態の変化やライフスタイルの要因によって世界のがんの負担が増大し続ける中、腫瘍学研究や臨床診療における調査、腫瘍トランスクリプトミクスの重要性は急上昇の一途をたどっています。研究開発への継続的な投資と、学界、産業界、ヘルスケアセクターの協力的な取り組みにより、世界の腫瘍トランスクリプトミクス市場は持続的な拡大が見込まれており、がんとの闘いにおける画期的なイノベーションと変革的な成果が期待されています。

市場促進要因

ゲノム技術の進歩

個別化医療に対する需要の高まり

がんの発生率と有病率の増加

主な市場課題

データの複雑性と解釈

標準化と再現性

主な市場動向

単一細胞トランスクリプトミクス

リキッドバイオプシー技術

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別（乳がん、肺がん、大腸がん、前立腺がん、黒色腫、その他）
  • 技術別（マイクロアレイ、リアルタイム定量、ポリメラーゼ連鎖反応（Q-PCR）、その他）
  • 製品別（消耗品、機器、ソフトウェア、サービス）
  • 用途別（診断および疾患プロファイリング、創薬、その他）
  • エンドユーザー別（バイオテクノロジー・製薬企業、研究・学術機関、その他）地域別
  • 企業別（2023年）
• 市場マップ
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋の腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第7章 欧州の腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 北米の腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 英国
  • カナダ
  • メキシコ

第9章 南米の腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの腫瘍トランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 腫瘍タイプ別
  • 技術別
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の腫瘍トランスクリプトミクス市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Thermo Fischer Scientific, Inc.
• Caris Life Sciences
• Illumina, Inc.
• NanoString Technologies, Inc.
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Standard BioTools Inc.
• Pacific Biosciences of California, Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Tumor Transcriptomics Market was valued at USD 5.67 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 6.34% through 2029. The Global Tumor Transcriptomics Market is witnessing a remarkable surge in growth, fueled by advancements in genomic research and personalized medicine. Tumor transcriptomics involves the study of gene expression patterns within tumor cells, offering invaluable insights into cancer biology, progression, and treatment responses. This burgeoning market is characterized by a plethora of innovative technologies and platforms, including next-generation sequencing (NGS), microarray analysis, and quantitative polymerase chain reaction (qPCR). These tools enable researchers and clinicians to profile gene expression levels, identify biomarkers, and elucidate molecular pathways implicated in various cancer types. One of the primary drivers propelling the growth of the tumor transcriptomics market is the increasing demand for precision oncology solutions. By deciphering the intricate molecular signatures of tumors, healthcare providers can tailor therapies to individual patients, optimizing treatment efficacy while minimizing adverse effects. Moreover, the advent of novel bioinformatics algorithms and data analytics tools has revolutionized data interpretation, facilitating the translation of complex genomic data into clinically actionable insights. This convergence of cutting-edge technologies and computational approaches is poised to redefine cancer diagnostics, prognostics, and therapeutics, ultimately revolutionizing patient care paradigms worldwide. As the global burden of cancer continues to escalate, fueled by demographic shifts and lifestyle factors, the significance of tumor transcriptomics in oncology research and clinical practice is poised to soar. With ongoing investments in research and development, coupled with collaborative efforts across academia, industry, and healthcare sectors, the Global Tumor Transcriptomics Market is poised for sustained expansion, promising groundbreaking innovations and transformative outcomes in the fight against cancer.

Key Market Drivers

Advancements in Genomic Technologies

Advancements in genomic technologies have revolutionized the landscape of cancer research and clinical practice, particularly within the realm of tumor transcriptomics. Next-generation sequencing (NGS), considered a cornerstone technology, has enabled high-throughput sequencing of tumor genomes and transcriptomes at unprecedented speeds and resolutions. NGS platforms offer comprehensive insights into the molecular mechanisms underlying cancer development, progression, and treatment responses by profiling gene expression patterns and detecting genomic alterations with unparalleled accuracy. Microarray analysis, another pivotal genomic technology, facilitates the simultaneous interrogation of thousands of genes within tumor samples, allowing researchers to characterize gene expression profiles and identify biomarkers associated with different cancer subtypes and disease states. Additionally, quantitative polymerase chain reaction (qPCR) technologies provide sensitive and precise quantification of gene expression levels, offering valuable validation and verification of transcriptomic findings. Moreover, advancements in single-cell transcriptomics technologies have emerged as a powerful tool for dissecting the heterogeneity of tumor cells, uncovering rare subpopulations, and elucidating dynamic transcriptional changes within the tumor microenvironment. These technological innovations have paved the way for more accurate cancer diagnostics, prognostics, and personalized treatment strategies, driving the Global Tumor Transcriptomics Market forward. The integration of genomic technologies with advanced bioinformatics and data analytics tools further enhances the interpretation and translation of complex genomic data into clinically actionable insights, fostering collaborations between academia, industry, and healthcare sectors to accelerate the pace of discovery and innovation in cancer research and therapy. As these technologies continue to evolve, they hold immense promise for revolutionizing our understanding of cancer biology and improving patient outcomes worldwide.

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is profoundly shaping the landscape of the Global Tumor Transcriptomics Market. Personalized medicine aims to tailor medical treatments to the individual characteristics of each patient, including their genetic makeup, molecular profile, and lifestyle factors. In oncology, personalized medicine holds immense promise for optimizing treatment outcomes while minimizing adverse effects, driving the adoption of tumor transcriptomics technologies. Tumor transcriptomics plays a pivotal role in personalized medicine by elucidating the molecular signatures of tumors and identifying specific genetic alterations and expression patterns associated with cancer subtypes and disease progression. By analyzing the transcriptomic profiles of tumors, healthcare providers can identify actionable biomarkers and therapeutic targets unique to each patient, guiding treatment decisions towards more effective and targeted interventions. The integration of tumor transcriptomics data with other omics technologies, such as genomics, proteomics, and metabolomics, further enhances the precision and predictive power of personalized medicine approaches. This multi-omics approach enables comprehensive molecular profiling of tumors, facilitating the development of tailored treatment regimens based on the individual molecular characteristics of each patient's cancer. As the field of personalized medicine continues to advance, fueled by technological innovations and research breakthroughs, the demand for tumor transcriptomics technologies is expected to escalate further. By enabling the delivery of tailored therapies that address the specific molecular drivers of cancer, tumor transcriptomics is poised to play a central role in driving the future of personalized oncology care, ultimately improving patient outcomes and revolutionizing cancer treatment paradigms worldwide.

Increasing Cancer Incidence and Prevalence

The escalating incidence and prevalence of cancer globally have underscored the urgent need for innovative approaches to cancer diagnosis, treatment, and management, thereby driving the growth of the Global Tumor Transcriptomics Market. Factors such as population growth, aging demographics, and lifestyle changes have contributed to the rising burden of cancer worldwide. As a result, there is a growing imperative to develop more effective and targeted therapeutic strategies to address the diverse spectrum of cancer types and subtypes. Tumor transcriptomics offers a powerful tool for understanding the molecular mechanisms underlying cancer development, progression, and treatment responses. By analyzing the gene expression patterns and molecular signatures of tumors, researchers can identify novel biomarkers, therapeutic targets, and molecular pathways implicated in cancer pathogenesis. This deeper understanding of tumor biology enables the development of precision oncology approaches that aim to tailor treatments to the unique molecular characteristics of each patient's cancer. The integration of tumor transcriptomics with other omics technologies, such as genomics, proteomics, and metabolomics, enables a comprehensive molecular profiling of tumors, facilitating the discovery of personalized treatment regimens and predictive biomarkers. As the incidence and prevalence of cancer continue to rise, fueled by demographic shifts and lifestyle factors, the demand for tumor transcriptomics technologies is expected to grow, driving innovation and transformative advancements in cancer research and clinical practice.

Key Market Challenges

Data Complexity and Interpretation

Data complexity and interpretation pose significant challenges in the Global Tumor Transcriptomics Market, hindering the effective utilization of transcriptomic data for cancer research and clinical applications. Tumor transcriptomics generates vast datasets comprising gene expression profiles, alternative splicing events, and non-coding RNAs, presenting challenges in data processing, analysis, and interpretation. The sheer volume and complexity of transcriptomic data require sophisticated bioinformatics tools and computational algorithms to identify biologically meaningful patterns and extract actionable insights. Moreover, transcriptomic data are inherently noisy and subject to various sources of variability, including biological heterogeneity, technical artifacts, and sample-specific factors. Ensuring the accuracy and reliability of data interpretation is crucial for distinguishing true signal from background noise and minimizing false discoveries. Additionally, integrating transcriptomic data with other omics datasets, such as genomics, proteomics, and metabolomics, further complicates data interpretation, requiring advanced statistical methods and multi-dimensional analysis approaches. Addressing the challenges of data complexity and interpretation in tumor transcriptomics requires interdisciplinary collaboration between bioinformaticians, biostatisticians, computational biologists, and domain experts. Standardizing experimental protocols, data analysis pipelines, and quality control measures is essential to ensure the reproducibility and comparability of results across different studies and laboratories. Moreover, developing user-friendly software tools and databases for data visualization, mining, and knowledge discovery can empower researchers and clinicians to unlock the full potential of transcriptomic data in advancing cancer research and precision oncology.

Standardization and Reproducibility

Standardization and reproducibility are crucial challenges facing the Global Tumor Transcriptomics Market, impacting the reliability and comparability of transcriptomic data across different studies and laboratories. The lack of standardized experimental protocols, sample processing techniques, and data analysis pipelines contributes to variability and inconsistency in transcriptomic results, hindering translational research and clinical validation efforts. Establishing standardized protocols and quality control measures is essential to ensure the reproducibility and reliability of transcriptomic data. This includes standardizing procedures for sample collection, RNA extraction, library preparation, sequencing, and data analysis. Implementing quality control metrics and reference standards can help monitor and minimize technical variability, ensuring data integrity and robustness. Moreover, promoting data sharing and collaboration through initiatives such as the Global Alliance for Genomics and Health (GA4GH) and the Cancer Genome Atlas (TCGA) facilitates the development of standardized data formats, metadata standards, and analysis pipelines. These collaborative efforts aim to harmonize transcriptomic data generation and analysis practices, enabling cross-study comparisons and meta-analyses to derive more robust and generalizable insights into cancer biology. Addressing the challenges of standardization and reproducibility in tumor transcriptomics requires concerted efforts from researchers, funding agencies, regulatory bodies, and industry stakeholders. By establishing clear guidelines, best practices, and quality assurance frameworks, the Global Tumor Transcriptomics Market can overcome these challenges and advance towards more reliable and reproducible transcriptomic profiling for cancer research and precision oncology applications.

Key Market Trends

Single-Cell Transcriptomics

Single-cell transcriptomics is a cutting-edge technology revolutionizing cancer research within the Global Tumor Transcriptomics Market. Traditionally, bulk tumor transcriptomics provided valuable insights into average gene expression profiles across heterogeneous cell populations. However, it failed to capture the intricacies of cellular diversity and functional heterogeneity within tumors. Single-cell transcriptomics enables the high-resolution profiling of individual tumor cells, uncovering rare cell populations, spatial organization, and dynamic transcriptional states within the tumor microenvironment. This approach offers unprecedented insights into tumor heterogeneity, revealing distinct cell types, subpopulations, and transcriptional programs implicated in cancer progression, metastasis, and therapeutic resistance. By dissecting the molecular landscape of tumors at the single-cell level, researchers can identify novel biomarkers, therapeutic targets, and signaling pathways driving tumorigenesis and treatment responses. Moreover, single-cell transcriptomics facilitates the development of personalized treatment strategies by tailoring therapies to the unique molecular characteristics of individual patients' tumors. By deciphering the transcriptional signatures of rare cell populations and therapy-resistant clones, clinicians can optimize treatment regimens and improve patient outcomes. As single-cell transcriptomics technologies continue to advance, with improvements in sensitivity, throughput, and scalability, they hold immense promise for revolutionizing cancer diagnostics, prognostics, and precision oncology approaches within the Global Tumor Transcriptomics Market..

Liquid Biopsy Technologies

Liquid biopsy technologies are emerging as a transformative tool within the Global Tumor Transcriptomics Market. Unlike traditional tissue biopsies, liquid biopsies involve the non-invasive analysis of tumor-derived biomarkers, including circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), and cell-free DNA (cfDNA), present in bodily fluids such as blood, urine, and cerebrospinal fluid. Liquid biopsies offer several advantages over conventional tissue biopsies, including their minimally invasive nature, ability to capture tumor heterogeneity, and real-time monitoring of treatment responses and disease progression. In the context of the Global Tumor Transcriptomics Market, liquid biopsy technologies enable the profiling of tumor-specific transcripts and gene expression patterns in circulation, providing valuable insights into cancer biology and therapeutic responses. Transcriptomic analysis of ctRNA extracted from liquid biopsies allows for the detection and monitoring of tumor-associated gene expression signatures, such as oncogenes, tumor suppressor genes, and drug resistance markers. These transcriptomic profiles can inform treatment decisions, predict treatment responses, and identify actionable targets for personalized therapies. Moreover, liquid biopsy-based transcriptomic profiling holds promise for early cancer detection, minimal residual disease monitoring, and longitudinal surveillance of treatment efficacy and disease recurrence. As liquid biopsy technologies continue to evolve and become more accessible, they are poised to revolutionize cancer diagnostics, prognostics, and precision oncology approaches within the Global Tumor Transcriptomics Market.

Segmental Insights

Tumor Type Insights

Based on tumor type, breast cancer segment dominated the Global Tumor Transcriptomics Market in 2023. This is ascribed due due to its high incidence, diverse molecular subtypes, and clinical heterogeneity. Transcriptomic profiling enables comprehensive characterization of breast tumors, guiding personalized treatment strategies based on individual gene expression patterns and molecular signatures. Moreover, the integration of transcriptomic data with other omics datasets facilitates biomarker discovery, therapeutic target identification, and predictive modeling, driving advancements in breast cancer research and precision oncology initiatives. This emphasis on transcriptomic analysis empowers clinicians to optimize treatment decisions, improve patient outcomes, and address the complex biology of breast cancer effectively.

Technology Insights

Based on technology, microarray segment dominated the Global Tumor Transcriptomics Market in 2023. This is ascribed due to its established technology, cost-effectiveness, and high throughput. Microarray platforms allow for simultaneous analysis of thousands of genes, providing comprehensive gene expression profiling in tumor samples. Moreover, microarrays are versatile and suitable for various sample types, including formalin-fixed paraffin-embedded (FFPE) tissues and archived specimens. Despite competition from newer technologies like next-generation sequencing (NGS), microarrays remain widely used in research and clinical settings, offering a reliable and accessible option for transcriptomic analysis in cancer research and diagnostics.

Regional Insights

North America leads the Global Tumor Transcriptomics Market, due to several factors. The region boasts advanced healthcare infrastructure, robust research funding, and a highly skilled workforce. Additionally, the presence of key market players, academic institutions, and research centers accelerates innovation and technology adoption. Moreover, supportive regulatory frameworks and a strong emphasis on personalized medicine initiatives further drive the growth of tumor transcriptomics in North America. These factors collectively contribute to the region's leading position in the global market.

Key Market Players

Thermo Fischer Scientific, Inc.

Caris Life Sciences.

Illumina, Inc.

NanoString Technologies, Inc.

10x Genomics, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche AG

Standard BioTools Inc.

Pacific Biosciences of California, Inc

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Transcriptomics Market, By Tumor Type:

Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Melanoma Others

Tumor Transcriptomics Market, By Technology:

Microarray Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) Others

Tumor Transcriptomics Market, By Product:

Consumables Instrument Software & Services

Tumor Transcriptomics Market, By Application:

Diagnostics and Disease Profiling Drug Discovery Others

Tumor Transcriptomics Market, By End User:

Biotechnology & Pharmaceutical Companies Research & Academic Institutions Others

Tumor Transcriptomics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tumor Transcriptomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others)
  • 5.2.2. By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others)
  • 5.2.3. By Product (Consumables, Instrument, Software & Services)
  • 5.2.4. By Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
  • 5.2.5. By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others) By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Tumor Type
  • 5.3.2. By Technology
  • 5.3.3. By Product
  • 5.3.4. By Application
  • 5.3.5. By End User
  • 5.3.6. By Region

6. Asia Pacific Tumor Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Technology
  • 6.2.3. By Product
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Tumor Transcriptomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. India Tumor Transcriptomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Japan Tumor Transcriptomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User
  • 6.3.4. South Korea Tumor Transcriptomics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Tumor Type
      • 6.3.4.2.2. By Technology
      • 6.3.4.2.3. By Product
      • 6.3.4.2.4. By Application
      • 6.3.4.2.5. By End User
  • 6.3.5. Australia Tumor Transcriptomics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Tumor Type
      • 6.3.5.2.2. By Technology
      • 6.3.5.2.3. By Product
      • 6.3.5.2.4. By Application
      • 6.3.5.2.5. By End User

7. Europe Tumor Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Technology
  • 7.2.3. By Product
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Tumor Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Tumor Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Tumor Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Tumor Transcriptomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Tumor Transcriptomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. North America Tumor Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Technology
  • 8.2.3. By Product
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United Kingdom Tumor Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. Canada Tumor Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Mexico Tumor Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User

9. South America Tumor Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Technology
  • 9.2.3. By Product
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tumor Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Tumor Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Tumor Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Tumor Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Technology
  • 10.2.3. By Product
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tumor Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Tumor Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Tumor Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User
  • 10.3.4. Egypt Tumor Transcriptomics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Tumor Type
      • 10.3.4.2.2. By Technology
      • 10.3.4.2.3. By Product
      • 10.3.4.2.4. By Application
      • 10.3.4.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Tumor Transcriptomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Thermo Fischer Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Caris Life Sciences
• 15.3. Illumina, Inc.
• 15.4. NanoString Technologies, Inc.
• 15.5. 10x Genomics, Inc.
• 15.6. Agilent Technologies, Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Standard BioTools Inc.
• 15.10. Pacific Biosciences of California, Inc

16. Strategic Recommendations

17. About Us & Disclaimer